Megalomicin inhibits HIV-1 replication and interferes with gp160 processing

Virology

Volumn 239, Issue 2, 1997, Pages 303-314

  José, Ester San ^a   Muñoz Fernández, M Angeles ^b   Alarcón, Balbino ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 160; MEGALOMICIN;

APOPTOSIS; ARTICLE; GENOME; HELPER CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRION; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031583841     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8872     Document Type: Article

References (30)

1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non human cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291.
2. Alarcón B., Lacal J. C., Fernández-Sousa J. M., Carrasco L. Screening for new compounds with anti-herpes activity. Antiviral Res. 4:1984;231-243.
3. Alarcón B., González M. E., Carrasco L. Megalomycin C a macrolide antibiotic that shows antiviral activity and blocks protein glycosylation. FEBS Lett. 231:1988;207-211.
4. Alarcón B., Ley S. C., Sánchez-Madrid F., Blumberg R. S., Ju S. T., Fresno M., Terhorst C. The CD3-g and CD3-d subunits of the T cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes. EMBO J. 10:1991;903-912.
5. Banda N. K., Bernier J., Kurahara D. K., Kurrle R., Raigwood N., Sekaly R. P., Finkel T. H. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J. Exp. Med. 176:1992;1099-1106.
6. Bedgood R. M., Stallcup M. R. A novel intermediate in processing of murine leukemia virus envelope glycoproteins: Proteolytic cleavage in the late Golgi region. J. Biol. Chem. 267:1992;7060-7065.
7. Berger E. G., Aegerter E., Mandel T., Hauri H. P. Monoclonal antibodies to soluble, human milk galactosyltransferase (lactose synthase A protein). Carbohydr. Res. 149:1986;23-33.
8. Bonay P., Munro S., Fresno M., Alarcón B. Intra-Golgi transport inhibition by megalomycin. J. Biol. Chem. 271:1996;3719-3726.
9. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62:1988;3779-3788.
10. Collier A. C., Coombs R. W., Schoenfeld D. A., Basset R. L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V. J., Friedman H. M., Merigan T. C., Reichman R. C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334:1996;1011-1017.
11. Dewar R. L., Vasudevachari M. B., Natarajan V., Salzman J. P. Biosynthesis and processing of human immunodeficiency virus type I envelope glycoproteins: Effects of monensin on glycosylation and transport. J. Virol. 63:1989;2452-2456.
12. Fleet G. W., Karpas A., Dwek R. A., Fellows L. E., Tyms A. S., Petursson S., Namgoong S. K., Ramsden N. G., Smith P. W., Son J. C., Wilson F., Witty D. R., Jacob G. S., Rademacher T. W. Inhibition of HIV replication by amino-sugar derivatives. FEBS Lett. 237:1988;128-132.
13. Gruters R. A., Neefjes J. J., Tersmette M., de Goede R. E. Y., Tulp A., Huisman H. G., Miedema F., Ploegh H. L. Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature. 330:1987;74-77.
14. Guo H. G., Veronese F. M., Tschachler E., Pal R., Kalyanaraman V. S., Gallo R. C., Reitz M. S. Jr. Characterization of an HIV-1 point mutation blocked the envelope glycoprotein cleavage. Virology. 174:1990;217-224.
15. Heimer G. V., Taylor C. E. Improved mountant for immunofluorescence preparations. J. Clin. Pathol. 27:1974;254-256.
16. Jacobsen H., Hanggi M., Ott M., Duncan I. B., Owen S., Andreoni M., Vella S., Mons J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J. Infect. Dis. 173:1996;1379-1387.
17. Kantanen M. L., Leinikki P., Kuismanen E. Endoproteolytic cleavage of HIV-1 gp160 envelope precursor occurs after exit from the trans-Golgi network (TGN). Arch. Virol. 140:1995;1441-1449.
18. Kärber G. Beiträge zur kollektiven behandlung pharmakologischer reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:1931;480-483.
19. Karpas A., Fleet G. W., Dwek R. A., Petursson S., Namgoong S. K., Ramsden N. G., Jacob G. S., Rodemacher T. W. Aminosugar derivatives of potential anti-human immunodeficiency virus agents. Proc. Natl. Acad. Sci. USA. 85:1988;9229-9233.
20. McCune J. M., Rabin L. B., Feinberg M. B., Lieberman M., Rosek J. C., Reyes G. R., Weissman I. L. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 53:1988;55-67.
21. Muñoz-Fernández M. A., Obregón E., Navarro J., Börner C., Gurbindo M. C., Sampelayo T. H., Fernández-Cruz E. Relationship of virologic, immunologic and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr. Res. 40:1996;597-602.
22. Navarro J., Punzón M. C., Pizarro A., Fernández-Cruz E., Fresno M., Muñoz-Fernández M. A. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumor necrosis factor synthesis or nuclear factor-κB activation. AIDS. 10:1996;469-475.
23. Pal R., Kalyanaraman V. S., Hoke G. M., Sarngadharan M. G. Processing and secretion of envelope glycoprotein of human immunodeficiency virus type 1 in the presence of trimming glucosidase inhibitor deoxynojirimycin. Intervirology. 30:1989;27-35.
24. Ratner L. Glucosidase inhibitors for treatment of HIV-1 infection. AIDS Res. Hum. Retroviruses. 8:1992;165-173.
25. Sánchez-Palomino S., Rojas J. M., Martínez M. A., Fenyö E. M., Nájera R., Domingo E., López-Galíndez C. Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture. J. Virol. 67:1993;2938-2943.
26. Shimizu H., Tsuchi H., Yoshida K., Morikawa S., Tsuruoka T., Yamamoto H., Ushijima H., Kitamura T. Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication. AIDS. 4:1990;975-979.
27. Stein B. S., Engleman E. G. Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex. J. Biol. Chem. 265:1990;2640-2649.
28. Sunkara P. S., Bowlin T. L., Lin P. S., Sjoerdsma A. Antiretroviral activity of castanospermine and deoxynojirimycin specific inhibitors of glycoprotein processing. Biochem. Biophys. Res. Commun. 148:1987;206-210.
29. Umezawa H. Index of Antibiotics from Actinomycetes. 1978;Japan Scientific Society Press, Tokyo.
30. M. J. Weinstein, G. M. Luederman, G. Ridge, G. M. Wagmar, J. A. Márquez, 1972.